Fitch Ratings November 19, 2021

Fitch Ratings-Chicago/New York-19 November 2021: US healthcare and pharmaceutical companies have maintained solid credit metrics during the coronavirus pandemic, with 3Q21 results in line to slightly better than expected for most sub-sectors, says Fitch Ratings. However, the risk that some issuers’ margins may be pressured in the near term is increasing, as labor inflation and supply chain disruptions lead to higher costs and potentially lost revenue. A temporary decline in profitability is not typically a downgrade trigger, making negative rating actions unlikely, particularly given healthcare’s relatively inelastic demand and track record of defending profitability.

Healthcare providers across numerous settings are challenged by the scarcity of workers, which is driving wages higher and leading to greater use of more expensive temporary...

Today's Sponsors

HealthITq
Premier
Health Edge

Today's Sponsors

Premier
Health Edge

Today's Sponsor

Amwell

 
Topics: Biotechnology, Pharma, Pharma / Biotech, Provider, Supply Chain, Technology
How Advocacy Groups and Patient Data Can Help Drive Health Equity
Taking Action to Address Health Equity in Oncology
New Enhancing Oncology Model Builds on Knowledge From the OCM
OCM Successor Puts Focus on Equity in Cancer Care—With Fewer Dollars for Services
RIP Medical Debt's growing business: 6 things to know